Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Phase 2 trial registration with no results posted; study is actively recruiting and designed to assess efficacy and safety of tirzepatide in binge-eating disorder.
This is a Phase 4 registry record with no reported results; it describes a planned interventional study in active recruitment with estimated enrollment of 200 participants and dual primary outcomes at 12 months.
This is a Phase 2 master protocol study registration with no results reported; enrollment is ongoing and primary outcomes are allocation metrics, not efficacy or safety findings.
This is a Phase 3 registry record with no reported results; the study is actively recruiting and designed to test a combination approach in a dual-disease population, but outcomes remain unreported.
FDA supplemental approval action for tirzepatide (Zepbound) efficacy; regulatory decisions do not themselves constitute clinical evidence and do not report trial outcomes.
This is a Phase 1/2 registry record for a planned interventional study with no results reported; enrollment is ongoing and no efficacy or safety data are available.
This is a Phase 2 interventional trial registration with planned enrollment of 285 participants; no results are reported in this registry record, making it an early-stage, ongoing study.